We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+18.11%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.6B
AUM Growth
+$241M
(+5.5%)
Cap. Flow
+$217M
Cap. Flow
% of AUM
4.71%
Top 10 Holdings %
Top 10 Hldgs %
38.55%
Holding
111
New
28
Increased
28
Reduced
20
Closed
14
Top Buys
| 1 |
Eli Lilly
LLY
|
+$126M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$95.6M |
| 3 |
Axsome Therapeutics
AXSM
|
+$76.9M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$72.2M |
| 5 |
Prothena Corp
PRTA
|
+$62.2M |
Top Sells
| 1 |
AstraZeneca
AZN
|
+$186M |
| 2 |
Johnson & Johnson
JNJ
|
+$160M |
| 3 |
McKesson
MCK
|
+$127M |
| 4 |
UnitedHealth
UNH
|
+$124M |
| 5 |
AbbVie
ABBV
|
+$116M |
Sector Composition
| 1 | Healthcare | 96.68% |
| 2 | Financials | 0.52% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.03T
| $326M | 7.08% |
1,007,000
+397,000
| +65% | +$126M |
|
2
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.15B
| $321M | 6.99% |
+4,052,000
| New | +$441M |
|
3
United Therapeutics
UTHR
$22.6B
| $203M | 4.42% |
970,200
+244,600
| +34% | +$54.7M |
|
4
Neurocrine Biosciences
NBIX
$17.3B
| $197M | 4.29% |
1,855,700
+388,100
| +26% | +$39.4M |
|
5
Arvinas
ARVN
$534M
| $193M | 4.2% |
4,343,500
+987,877
| +29% | +$48M |
|
6
argenx
ARGX
$54B
| $174M | 3.78% |
491,800
-80,700
| -14% | -$29.9M |
|
7
Biogen
BIIB
$29.1B
| $160M | 3.48% |
600,000
+159,434
| +36% | +$33.9M |
|
8
Vertex Pharmaceuticals
VRTX
$121B
| $148M | 3.23% |
512,800
-280,200
| -35% | -$80.6M |
|
9
Syndax Pharmaceuticals
SNDX
$2.08B
| $134M | 2.92% |
5,586,900
+136,900
| +3% | +$3.07M |
|
|
10
Prothena Corp
PRTA
$441M
| $119M | 2.59% |
+1,967,000
| New | +$62.2M |
|
11
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $117M | 2.55% |
1,480,000
-395,000
| -21% | -$33.3M |
|
12
Acadia Healthcare
ACHC
$2.97B
| $109M | 2.36% |
1,389,200
+354,200
| +34% | +$28.3M |
|
|
AKRO
13
DELISTED
Akero Therapeutics
AKRO
| $106M | 2.31% |
+3,122,000
| New | +$47.8M |
|
|
14
Sarepta Therapeutics
SRPT
$1.86B
| $105M | 2.28% |
+948,200
| New | +$95.6M |
|
15
Humana
HUM
$49B
| $103M | 2.24% |
212,000
-200,300
| -49% | -$97.4M |
|
16
Boston Scientific
BSX
$64B
| $98.3M | 2.14% |
2,538,600
+13,600
| +0.5% | +$546K |
|
17
Immunocore
IMCR
$1.76B
| $97.6M | 2.12% |
2,079,100
+729,100
| +54% | +$34.7M |
|
|
KRTX
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $97.1M | 2.11% |
431,800
+227,230
| +111% | +$46M |
|
19
Elevance Health
ELV
$84.8B
| $94.3M | 2.05% |
207,600
-233,400
| -53% | -$112M |
|
|
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $91.7M | 2% |
1,482,200
-374,700
| -20% | -$26.2M |
|
21
Zentalis Pharmaceuticals
ZNTL
$340M
| $91.5M | 1.99% |
4,223,100
+637,219
| +18% | +$17.4M |
|
22
Avantor
AVTR
$7.65B
| $88.6M | 1.93% |
4,522,600
-2,130,100
| -32% | -$57.1M |
|
23
Ultragenyx Pharmaceutical
RARE
$3.12B
| $85M | 1.85% |
2,051,600
+572,100
| +39% | +$29.4M |
|
24
Natera
NTRA
$39.7B
| $76M | 1.65% |
1,735,000
+365,900
| +27% | +$17.4M |
|
|
25
Axsome Therapeutics
AXSM
$12.2B
| $68.7M | 1.49% |
+1,538,600
| New | +$76.9M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH